RE:RE:RE:RE:RE:Type C Meeting Timingsyes, this seems to support the notion that oncy has submitted its package:
Ongoing discussions with our clinical collaborators and partners have helped us to prepare a robust, compelling briefing document,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. “We eagerly anticipate our discussion with the FDA to align on the design and objectives of the registrational trial for pelareorep in metastatic breast cancer, a critical step towards bringing this innovative treatment to patients.
and the fda type c timeline site states this:
For Type C meetings that are requested as early consultations on the use of a new surrogate endpoint to be used as the primary basis for product approval in a proposed context of use, the meeting package is due at the time of the meeting request.
for once, oncy appears to be moving toward registration faster than one could have hoped.